Clinical Trial Update: Efficacy and Safety of Canakinumab in Patients With Colchicine Resistant Familial Mediterranean Fever [Phase 2]

View source ↗

Summary

A phase 2 trial evaluating the efficacy and safety of canakinumab in patients with colchicine-resistant familial Mediterranean fever has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Mediterranean Fever

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Familial Mediterranean Fever | Phase 2 | Status: COMPLETED